Overview

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Glaxo Wellcome

Treatments:

Lamivudine
Zidovudine